As global leaders gather for Unstoppable Africa 2026, Roche (www.Roche.com) has reaffirmed its commitment to advancing healthcare as a primary driver of economic resilience across the continent.
Roche has reported a phase 3 win for sefaxersen in kidney disease, teeing up talks with regulators about the path to approval for the Ionis-partnered, would-be blockbuster candidate.
Western pharmaceutical companies are urging the Trump administration to allow them to keep doing deals with Chinese companies for drug candidates
STAT•Ed Silverman22 Sept
A phase 2 trial of Roche’s dual GLP-1/GIP receptor agonist has hit its primary endpoints, painting the drug candidate as a potential treatment for people with Type 2 diabetes and overweight or obesity.
A gene therapy approved for Sanfilippo syndrome, good and bad news for Xenon Pharma, and more biotech news
STAT•Meghana Keshavan, Adam Feuerstein,and Margaret Manto18 Sept
Roche’s T-cell engager portfolio has notched another milestone, as a phase 3 trial of the company’s Lunsumio met its primary endpoint in earlier-line follicular lymphoma.
Roche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments for immunology and inflammation diseases.
MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate. The small-cell lung cancer trial hit its primary endpoint, although the B7-H3-directed ADC’s median overall survival fell short of the bar set by GSK’s rival asset.
AI-driven drug discovery could revolutionize treatment approaches, offering new hope for complex diseases and reshaping pharmaceutical R&D.
CryptoBriefing•Editorial Team5 Aug